question | NBIX Message Board Posts


Neurocrine Biosciences, Inc.

  NBIX website

NBIX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  45057 of 45065  at  9/18/2018 3:20:42 PM  by

ashtonb22


 In response to msg 45056 by  grega22
view thread

Re: question

I don't see why we shouldn't see the fruits of the expanded sales force in this quarter (3rd quarter). It is supposed to be entirely complete in the 4th so you would think new sales reps have been out there in the 3rd quarter. As far as impact, it should increase the revenue, but maybe that is already baked into expectations? Who knows. Revenue estimates are at $151 million. Minus the $40 million milestone, Ingrezza and Orlissa revenues have to beat $111 million which is about $15 million more than last quarter. Revenue jumped 25.5 million from 1 qtr to 2nd qtr without Orlissa. So a $15 million bump seems doable. Playing devil's advocate, revenue only increased 7 million from 4th qtr to 1st qtr this year, but we had the donut hole thing as well as some other headwinds. However, I do think that this is somewhat what Gorman was talking about revenue being lumpy from quarter to quarter. JMO.


 printer-friendly     add to library       Recs: 0  
   Views: 142 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
45058 Re: question bier4me 1 9/18/2018 3:58:29 PM




Financial Market Data provided by
.
Loading...